Skip to main content

Table 3 Sensitivity, specificity, PPV and NPV of the different tests

From: Performance of p16/Ki67 immunostaining, HPV E6/E7 mRNA testing, and HPV DNA assay to detect high-grade cervical dysplasia in women with ASCUS

Test

Endpoint

Sensitivity

Specificity

PPV

NPV

Youden

  

(95% CI)

(95% CI)

(95% CI)

(95% CI)

 

HPV DNA

CIN2+

98.2% (90.2, 99.7)

17.5% (13.2, 22.7)

20.7% (16.2, 26.1)

97.7% (88.2, 99.6)

15.7

CIN3+

100% (86.7, 100)

16.0% (12.1, 20.8)

9.8% (6.7, 14.0)

100% (92.0, 100)

16.0

HPV E6/E7 mRNA

CIN2+

87.0% (75.6, 93.6)

42.7% (36.7, 48.9)

25.0% (19.4, 31.7)

93.8% (87.7, 96.9)

29.7

CIN3+

88.0% (70.0, 95.8)

39.6% (34.0, 45.5)

11.7% (7.9, 17.1)

97.3% (92.4, 99.1)

27.6

p16/Ki67

CIN2+

98.2% (90.2, 99.7)

82.5% (77.3, 86.8)

55.2% (45.3, 64.8)

99.5% (97.3, 99.9)

80.7

CIN3+

100% (86.7, 100)

74.2% (68.7, 79.0)

26.0% (18.3, 35.6)

100% (98.2, 100)

74.2

  1. Note: PPV = positive predictive value; NPV = negative predictive value. Results in % with 95% confidence interval (95% CI)